Financial Performance - Revenue for Q3 2022 was ¥267,445,171.54, a decrease of 39.95% compared to the same period last year[4] - Net profit attributable to shareholders was -¥10,553,027.29, a decline of 63.26% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,176,122.79, down 59.10% from the previous year[4] - Basic and diluted earnings per share were both -¥0.0282, a decrease of 64.72% compared to the same period last year[4] - The net profit attributable to the parent company was a loss of CNY 12,096,001.39, an improvement compared to a loss of CNY 42,229,317.91 in the previous period[19] - Basic and diluted earnings per share were both reported at -0.0323, an improvement from -0.1242 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,611,177,295.20, a decrease of 6.76% from the end of the previous year[4] - As of September 30, 2022, total current assets amounted to CNY 397,463,271.52, a decrease from CNY 546,039,989.40 at the beginning of the year, representing a decline of approximately 27.2%[14] - Total non-current assets reached CNY 1,213,714,023.68, an increase from CNY 1,181,909,973.11 at the start of the year, indicating a growth of about 2.7%[15] - The total assets of the company were CNY 1,611,177,295.20, down from CNY 1,727,949,962.51, reflecting a decrease of approximately 6.7%[15] - Total current liabilities were CNY 931,775,922.03, a reduction from CNY 1,045,237,076.35, showing a decline of around 10.9%[15] - The company's total liabilities amounted to CNY 943,063,196.72, down from CNY 1,061,312,988.31, representing a decrease of about 11.1%[15] - The company’s total equity attributable to shareholders reached CNY 668,114,098.48, slightly up from CNY 666,636,974.20[18] Cash Flow - Cash flow from operating activities showed a net outflow of -¥41,132,208.79, a significant decline of 171.07%[4] - Cash flow from operating activities showed a net outflow of CNY 41,132,208.79, contrasting with a net inflow of CNY 57,873,864.42 in the previous period[19] - The net cash flow from investment activities was 11,796,141.15, a significant improvement compared to -92,691,397.23 in the previous period[20] - Total cash inflow from financing activities reached 199,790,100.00, up from 136,000,000.00 in the prior period[20] - The net cash flow from financing activities was 5,929,296.41, contrasting with -96,660,240.95 in the previous period[20] - The cash and cash equivalents at the end of the period totaled 11,693,152.81, down from 95,348,563.04 at the end of the previous period[20] - The company experienced a net decrease in cash and cash equivalents of 21,273,873.63 during the quarter[20] - The total cash outflow from investment activities was 54,218,722.08, compared to 92,669,182.62 in the previous period[20] - The company received 101,550,000.00 in cash from investment absorption during the quarter[20] - The cash paid for debt repayment was 82,000,000.00, a decrease from 122,041,192.54 in the previous period[20] - The impact of exchange rate changes on cash and cash equivalents was 2,132,897.60, compared to 31,368.60 in the previous period[20] Shareholder Information - The top ten shareholders collectively hold 58.56% of the company's shares, with Jiangsu Suhua Group Co., Ltd. being the largest shareholder at 9.18%[12] - The company has no preferred shareholders as of the reporting period[13] Operational Activities - The company reported a 375.96% increase in other non-current assets, totaling ¥94,020,881.37 due to reclassification of long-term assets[9] - Research and development expenses decreased by 71.50% to ¥3,138,082.33 compared to the same period last year[10] - The company received government subsidies amounting to ¥3,210,265.53, an increase of 146.61% year-on-year[10] - The company reported a significant increase in cash received from the disposal of fixed assets, amounting to ¥6,014,863.23, a rise of 27176.16%[10] - Total operating revenue for the period reached CNY 1,091,224,761.19, a slight increase from CNY 1,085,671,226.21 in the previous period, representing a growth of approximately 0.5%[17] - Total operating costs decreased to CNY 1,120,927,109.52 from CNY 1,143,331,222.90, marking a reduction of about 2.0%[17] - Research and development expenses significantly decreased to CNY 3,138,082.33 from CNY 11,010,052.54, a reduction of approximately 71.5%[17] - Sales expenses were reduced to CNY 7,901,158.93 from CNY 24,103,059.75, indicating a decrease of about 67.2%[17] - The company reported a significant increase in other income to CNY 3,210,265.53 from CNY 1,301,750.00, representing a growth of approximately 146.4%[17] Audit Information - The third quarter report was not audited[21]

Financial Performance - The company's revenue for Q3 2023 was ¥236,491,965.97, a decrease of 11.57% compared to the same period last year[4] - Total revenue for Q3 2023 was CNY 763,015,745.63, a decrease of 30.0% compared to CNY 1,091,224,761.19 in the same period last year[21] - The net profit attributable to shareholders was -¥44,314,002.86, representing a decline of 319.92% year-on-year[4] - Operating profit for Q3 2023 was CNY -131,629,535.52, compared to CNY -18,894,383.69 in Q3 2022, indicating a significant decline in profitability[21] - The net loss for the third quarter was CNY 135.98 million, compared to a net loss of CNY 12.10 million in the previous year, indicating a significant increase in losses[22] - The total comprehensive loss for the quarter was CNY 135.70 million, compared to a loss of CNY 12.10 million in the previous year[22] Earnings and Shareholder Information - The basic earnings per share for the period was -¥0.1186, down 320.70% from the previous year[4] - The basic and diluted earnings per share for the third quarter were both CNY -0.3638, compared to CNY -0.0323 in the previous year[22] - The total number of ordinary shareholders at the end of the reporting period was 16,909, with no preferred shareholders[13] - The top ten shareholders hold a combined 70.32% of the company's shares, with the largest shareholder, Zheng Xu, holding 18.04%[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,460,768,263.53, a decrease of 1.00% from the end of the previous year[4] - Non-current assets decreased to CNY 1,061,735,281.47 from CNY 1,115,270,289.88, a decline of 4.8%[18] - Total current liabilities increased to CNY 1,150,600,333.84, up 10.9% from CNY 1,036,911,460.90[19] - The company’s total equity attributable to shareholders decreased by 37.59% to ¥223,186,388.39 compared to the previous year[4] Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥114,734,899.63, a decline of 178.94% year-to-date[4] - The cash flow from operating activities showed a net outflow of CNY 114.73 million, worsening from a net outflow of CNY 41.13 million in the same period last year[23] - The cash flow from financing activities generated a net inflow of CNY 170.55 million, a substantial increase from CNY 5.93 million in the same period last year[24] - The company’s cash and cash equivalents were impacted by exchange rate fluctuations, resulting in a decrease of 88.60% in the cash effect from foreign exchange[11] Research and Development - Research and development expenses increased by 106.74% to ¥6,487,821.43, indicating a focus on innovation[10] - Research and development expenses increased to CNY 6,487,821.43, up 106.0% from CNY 3,138,082.33 year-on-year[21] Other Income and Expenses - The company reported a significant increase in other income by 46.27% to ¥4,695,645.56, primarily due to tax exemptions[10] - The company incurred operating expenses of CNY 535.75 million, a decrease from CNY 1,076.80 million in the same period last year[23] - The company received CNY 8.33 million in tax refunds during the quarter, down from CNY 43.52 million in the same period last year[23] Share Transactions and Acquisitions - The company completed the transfer of 33,610,000 shares from a major shareholder, representing 8.99% of the total share capital, to Hainan Wenqin Private Fund Management[15] - The company acquired 51% of Anhui Xuhe New Energy Technology Co., Ltd. for RMB 67,523,490, becoming its controlling shareholder[16] - The company is actively expanding its market presence through strategic acquisitions and investments in new technologies[16] Stock Structure - The company’s stock structure changed post-acquisition, with Bluefeng holding 51%, Zheng Xu 31.85%, and other investors holding the remainder[16]

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-097 具体详见 2023 年 10 月 31 日刊登在公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）及《上海证券报》、《证券时报》、《中国证券报》上的 相关公告。 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届监事会第四次 会议于 2023 年 10 月 30 日以通讯表决方式召开。本次会议通知已于 2023 年 10 月 27 日以微信、电子邮件的方式通知全体监事。本次会议由公司监事会主席韩 宜辰先生主持，应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开及 表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、监事会会议审议情况 （一）审议通过《关于公司 2023 年第三季度报告的议案》 江苏蓝丰生物化工股份有限公司 经审核，监事会认为公司《2023 年第三季度报告》的编制程序符合法律、行 政法规的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任 何虚假记载、 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-096 江苏蓝丰生物化工股份有限公司 第七届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第五次 会议于 2023 年 10 月 30 日以通讯表决方式召开。本次会议通知已于 2023 年 10 月 27 日以微信、电子邮件的方式通知全体董事。本次会议由公司董事长郑旭先 生主持，应出席董事 8 人，实际出席董事 8 人，监事和高管列席会议。本次会议 的召集、召开及表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于公司 2023 年第三季度报告的议案》 经审核，董事会认为公司《2023 年第三季度报告》的编制程序符合法律、行 政法规的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任 何虚假记载、误导性陈述或者重大遗漏。 表决结果：8 票同意，0 票反对，0 票弃权。 具体详见 2023 年 10 月 31 日刊登在公司指定信息披 ...

公司全体独立董事对此议案发表了同意的独立意见。具体详见 2023 年 10 月 17 日刊登在公司指定信息披露网站巨潮资讯网（www.cninfo.com.cn）及《上海 证券报》、《证券时报》、《中国证券报》上的相关公告。 证券代码：002513 证券简称：蓝丰生化 公告编号：2023-094 江苏蓝丰生物化工股份有限公司 第七届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第四次 会议于 2023 年 10 月 16 日以通讯表决方式召开。本次会议通知已于 2023 年 10 月 13 日以微信、电子邮件的方式通知全体董事。本次会议由公司董事长郑旭先 生主持，应出席董事 8 人，实际出席董事 8 人，监事和高管列席会议。本次会议 的召集、召开及表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于变更总经理及法定代表人的议案》 基于公司经营管理和长远发展战略考虑，郑旭先生于近日向公司董事会递交 了书面辞 ...

（以下无正文） 江苏蓝丰生物化工股份有限公司 独立董事：袁坚、刘兴翀、汤健 2023 年 10 月 16 日 根据中国证监会《关于在上市公司建立独立董事制度的指导意见》、《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》、《公司 章程》等有关规定，作为江苏蓝丰生物化工股份有限公司（以下简称"公司"） 独立董事，基于独立判断的立场，本着对公司、全体股东负责的态度，现就公司 第七届董事会第四次会议审议的有关事项发表独立意见如下： 一、关于变更总经理及法定代表人的独立意见 经核查，本次公司总经理候选人的提名、聘任程序符合《公司法》《深圳证 券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等相关法律法规和规范性文件及《公司章程》的有关规定， 程序合法有效，不存在损害公司及其他股东利益的情况。 经审阅本次董事会聘任的公司总经理候选人履历等相关资料，我们认为本次 聘任的总经理具备相关专业知识和技能，任职资格符合《公司法》和《公司章程》 等有关规定，未受过中国证监会及其他有关部门的处罚和证券交易所的纪律处分； 未有因涉嫌犯罪被司法机关立案侦查或者涉嫌违 ...

根据《公司章程》"第八条 董事长或总经理为公司的法定代表人"，李质 证券代码：002513 证券简称：蓝丰生化 公告编号：2023-093 江苏蓝丰生物化工股份有限公司 关于变更总经理及法定代表人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、关于公司总经理辞职的情况 江苏蓝丰生物化工股份有限公司(以下简称"公司")董事长兼总经理郑旭先 生，基于公司经营管理和长远发展战略考虑，于近日向公司董事会递交了书面辞 职报告，申请辞去公司总经理职务，辞职后将继续担任公司董事长及董事会战略 委员会主任委员、提名委员会委员、薪酬与考核委员会委员，将继续在战略层面 支持公司发展。郑旭先生的辞职报告自送达公司董事会之日起生效。 截至本公告披露日，郑旭是公司控股股东、实际控制人，郑旭先生持有公司 67,457,432 股股份，占公司总股本 18.04%，其与安徽巽顺投资合伙企业（有限 合伙）（以下简称"巽顺投资"）为一致行动关系，巽顺投资持有公司 28,601,123 股股票，占公司总股本的 7.65%。 公司董事会对郑旭先生担任公司总经理期间为公司发展所做出的卓越贡献 ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-095 江苏蓝丰生物化工股份有限公司 关于购买旭合科技 51%股权完成工商变更登记 并换发营业执照的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、对外投资基本情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"、"蓝丰生化"）于 2023 年 9 月 22 日、10 月 10 日分别召开了第七届董事会第三次会议、第七届监事会 第三次会议及 2023 年第二次临时股东大会，审议通过了《关于购买安徽旭合新 能源科技有限公司 51%股权暨关联交易的议案》，本次购买股权事项完成后，安 徽旭合新能源科技有限公司（以下简称"旭合科技"）股权结构将变更为：蓝丰 生化持有 51%股权、郑旭持有 31.85%股权、安徽瓴先新能源投资合伙企业（有限 合伙持有 14.70%股权、安徽巽顺投资合伙企业（有限合伙）持有 2.45%股权。具 体内容详见公司 2023 年 9 月 23 日在指定信息媒体披露的《江苏蓝丰生物化工股 份有限公司关于安徽旭合新能源科技有限公司 51%股权暨关联交易的公告》（公 告编号：20 ...

北京市万商天勤律师事务所 关于 江苏蓝丰生物化工股份有限公司 2023 年第二次临时股东大会 的法律意见书 北京市朝阳区建国门外大街 8 号北京国际财源中心 A 座 32 层 100022 电话: +86 10 82255588 www.vtlaw.cn 北京 深圳 上海 成都 武汉 西安 长沙 杭州 海口 南京 广州 香港 北京市万商天勤律师事务所 关于江苏蓝丰生物化工股份有限公司 本所律师同意将本法律意见书随公司本次股东大会决议一并予以公告，并依法对 本法律意见书承担相应的责任。 本所律师根据《股东大会规则》第五条的要求，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对公司提供的有关文件和本次股东大会的有关事项进行了 核查和验证，并现场出席了公司本次股东大会。现就公司本次股东大会的召开及表决 等情况出具法律意见如下： 一、本次股东大会的召集、召开程序 （一）本次股东大会由公司董事会召集。2023 年 9 月 22 日，公司召开第七届董 事会第三次会议，会议决定于 2023 年 10 月 10 日召开 2023 年第二次临时股东大会。 （二）公司已于 2023 年 9 月 23 日在巨潮资讯网（ht ...

证券代码：002513 证券简称：蓝丰生化 公告编号：2023-090 江苏蓝丰生物化工股份有限公司 关于公司持股 5%以上股东股份被司法拍卖完成过户 二、股份过户登记完成情况 根据结算公司系统显示，上述无限售流通股 9,816,589 股和限售股 23,793,411 股，合计 33,610,000 股，已于 2023 年 9 月 25 日完成过户登记手 续。过户完成后，海南闻勤私募基金管理合伙企业(有限合伙)-闻勤顺为 1 号私 募证券投资基金（以下简称"海南闻勤"）持有公司股份 33,610,000 股，占公 司总股本比例为 8.99%。本次过户前后，王宇先生及海南闻勤持有公司股份的 1 暨权益变动提示性的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 江苏蓝丰生物化工股份有限公司（以下简称"公司"）近日通过中国证券登 记结算有限责任公司深圳分公司（以下简称"结算公司"）系统查询，获悉公司 持股 5%以上股东王宇先生被司法拍卖的无限售流通股 9,816,589 股和限售股 23,793,411 股，合计 33,610,000 股，已完成过户登记手续。 ...